EverCyte

Executive Summary

EverCyte is a Vienna-based biotechnology company specializing in human primary-like cell models for in vitro test systems. Founded in 2006, the company addresses a critical bottleneck in preclinical drug development: the lack of standardized, physiologically relevant models that accurately predict human responses. By leveraging proprietary cell lines that mimic primary human cells, EverCyte enables the creation of reproducible organ-on-a-chip and other advanced platforms. This technology has the potential to reduce animal testing, accelerate drug discovery, and lower attrition rates in clinical trials. Currently at the pre-clinical stage, EverCyte is well-positioned to partner with pharmaceutical companies and contract research organizations seeking more predictive preclinical tools. The growing regulatory push for alternative methods to animal testing further supports the company's market opportunity.

Upcoming Catalysts (preview)

• Q3 2026Pharmaceutical Partnership for Organ-on-a-Chip Validation60% success
• Q4 2026Series A Funding Round70% success
• Q2 2026Publication of Key Validation Data in Peer-Reviewed Journal80% success